JP2003516316A - 腸癌阻止剤としてのウログアニリン - Google Patents

腸癌阻止剤としてのウログアニリン

Info

Publication number
JP2003516316A
JP2003516316A JP2001528206A JP2001528206A JP2003516316A JP 2003516316 A JP2003516316 A JP 2003516316A JP 2001528206 A JP2001528206 A JP 2001528206A JP 2001528206 A JP2001528206 A JP 2001528206A JP 2003516316 A JP2003516316 A JP 2003516316A
Authority
JP
Japan
Prior art keywords
composition
amino acid
uroguanylin
group
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001528206A
Other languages
English (en)
Japanese (ja)
Inventor
シャイルバーイ、クンワール
カリー、マーク、ジー
Original Assignee
ファルマシア コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファルマシア コーポレイション filed Critical ファルマシア コーポレイション
Publication of JP2003516316A publication Critical patent/JP2003516316A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2001528206A 1999-10-06 2000-10-04 腸癌阻止剤としてのウログアニリン Withdrawn JP2003516316A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15795099P 1999-10-06 1999-10-06
US60/157,950 1999-10-06
PCT/US2000/021998 WO2001025266A1 (en) 1999-10-06 2000-10-04 Uroguanylin as an intestinal cancer inhibiting agent

Publications (1)

Publication Number Publication Date
JP2003516316A true JP2003516316A (ja) 2003-05-13

Family

ID=22566032

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001528206A Withdrawn JP2003516316A (ja) 1999-10-06 2000-10-04 腸癌阻止剤としてのウログアニリン

Country Status (4)

Country Link
EP (1) EP1220872A1 (de)
JP (1) JP2003516316A (de)
AU (1) AU7700400A (de)
WO (1) WO2001025266A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2944648B1 (de) 2001-03-29 2019-11-13 Bausch Health Ireland Limited Guanylat-Cyclase-Rezeptor-Agonisten zur Behandlung von Organentzündung
RU2543350C2 (ru) 2003-01-28 2015-02-27 Айронвуд Фармасьютикалз, Инк. Способы и композиции для лечения желудочно-кишечных расстройств
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004071436A2 (en) 2003-02-10 2004-08-26 Thomas Jefferson University The use of gcc ligands
EP2526958B1 (de) 2003-06-13 2017-10-18 Ironwood Pharmaceuticals, Inc. Verfahren und Zusammensetzungen zur Behandlung von Magen-Darm-Störungen
US7494979B2 (en) 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
KR20100061480A (ko) * 2007-09-11 2010-06-07 몬도바이오테크 래보래토리즈 아게 치료제로서의 글루카곤（１－２９） 단독 또는 뉴로펩티드 ｗ３０과의 배합물의 용도
EP2810951B1 (de) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
EP2296685B1 (de) 2008-06-04 2015-09-02 Synergy Pharmaceuticals Inc. Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
ES2608050T3 (es) 2008-12-03 2017-04-05 Synergy Pharmaceuticals Inc. Formulaciones de agonistas de guanilato ciclasa C y métodos de uso
JP5921545B2 (ja) 2010-08-11 2016-05-24 アイアンウッド ファーマシューティカルズ インコーポレイテッド リナクロチドの安定な製剤
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012037380A2 (en) 2010-09-15 2012-03-22 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2013016662A1 (en) * 2011-07-28 2013-01-31 Memorial Sloan-Kettering Cancer Center Diagnosis and treatment of parkinson's disease
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US20210263047A1 (en) * 2020-01-31 2021-08-26 Sequela, Inc. Biomarker, methods, and compositions thereof for evaluation or management of kidney function or diagnosing or aid in diagnosing kidney dysfunction or kidney disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879656A (en) * 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US5962220A (en) * 1993-10-26 1999-10-05 Thomas Jefferson University Compositions that specifically bind to colorectal cells and methods of using the same
DE69723580T2 (de) * 1996-05-03 2004-06-03 Thomas Jefferson University Impfstoff gegen metastasierenden kolorektalkrebs.
AU2530199A (en) * 1998-02-06 1999-08-23 Nycomed Imaging As Targeting immunoreagents useful in therapeutic and diagnostic compositions and methods

Also Published As

Publication number Publication date
AU7700400A (en) 2001-05-10
WO2001025266A1 (en) 2001-04-12
EP1220872A1 (de) 2002-07-10

Similar Documents

Publication Publication Date Title
JP2003516316A (ja) 腸癌阻止剤としてのウログアニリン
Kobayashi et al. Thymosin-β4 regulates motility and metastasis of malignant mouse fibrosarcoma cells
Shailubhai et al. Uroguanylin treatment suppresses polyp formation in the Apc Min/+ mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP
US9248163B2 (en) Insulin-like growth factor binding protein 7 for treatment of cancer
US20090208473A1 (en) Compositions and methods to modulate cell membrane resealing
Nolten et al. Hepatocyte nuclear factor 1 alpha activates promoter 1 of the human insulin-like growth factor I gene via two distinct binding sites.
Ye et al. bcl-2/bax expression and p53 gene status in human bladder cancer: relationship to early recurrence with intravesical chemotherapy after resection
KR20120051258A (ko) Ｇｋｎ １을 함유하는 항암용 조성물
US7485619B2 (en) Antimicrobial agent
Higgins Antigenic and cytoarchitectural “markers” of differentiation pathways in normal and malignant colonic epithelial cells
US20220362228A1 (en) Compositions and methods for treating chemotherapy resistant cancer
Saito et al. Disruption of E‐cadherin‐mediated cell adhesion systems in gastric cancers in young patients
WO2000023100A9 (en) Genes and proteins predictive and therapeutic for renal disease and associated disorders
US20150110778A1 (en) Compositions comprising mg53 and methods for the treatment and prevention of airway injury
Osipo et al. Loss of insulin-like growth factor II receptor expression promotes growth in cancer by increasing intracellular signaling from both IGF-I and insulin receptors
US20150087604A1 (en) Anti-fatty acid synthase polypeptide and use thereof
Pehlivan et al. Secreted Wnt antagonists in leukemia: A road yet to be paved
KR20180066237A (ko) 항-암 및 항-염증 치료제 및 이의 방법
TW201200151A (en) Methods and compositions related to reduced MET phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells
Hughes et al. Adenomatous polyposis coli truncation alters cytoskeletal structure and microtubule stability in early intestinal tumorigenesis
KR20220008307A (ko) Gly101val 돌연변이를 수반하는 bcl-2 매개 암의 치료에 사용하기 위한 bcl-2 억제제
WO2006086891A1 (en) Insulin-like growth factor binding protein-4 compounds and methods for inhibiting angiogenesis and tumor growth in mammalian cells
US20120264804A1 (en) T type calcium channel blockers and the treatment of diseases
WO2024024895A1 (ja) 肺腺癌の治療剤
JP4744140B2 (ja) アンドロゲン調節性ｐｍｅｐａ１遺伝子および癌細胞増殖を抑制するための同遺伝子の使用方法

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20071204